FDA to review Roche's bladder cancer drug on priority basis

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted a priority review status to Roche's immunotherapy to treat advanced bladder cancer, the Swiss pharmaceutical maker said on Tuesday.

http://ift.tt/1S1cGRu

from Reuters: Health News
via animenewspro